FINHUB Insights

VRTX · Q2 FY25 · Apr 1 – Jun 30, 2025

Vertex Pharmaceuticals Q2 FY25: where the revenue came from and where it went

Vertex Pharmaceuticals Q2 FY25: revenue $3B (+12% year over year). Net profit $1B. Largest cohort TRIKAFTAKAFTRIO $2.6B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2025
Reported
Aug 5, 2025 10-Q
Sankey diagram of Vertex Pharmaceuticals's income statement for Q2 FY25: revenue of $3 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$3B +12% year over year
Gross profit$2.6B 86% margin
Operating profit$1.2B 39% margin
Net profit$1B 35% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
ItemValueShare of revenueYear over year
Revenue 3 100% +12%
TRIKAFTAKAFTRIO 2.6 87% +4%
Manufactured Product Other 0.2 7% +20%
ALYFTREK 0.2 7%
Cost of revenue−0.413%
Gross profit2.686% margin+0pp
SG&A−0.414%+0pp
Other−133%+0pp
Operating profit1.239% margin+172pp
Tax−0.3
Net profit135%+171pp
Filing on EDGAR More quarters of VRTX

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters